Idarucizumab An Imperfect Reversal Agent for Dabigatran

We waited with bated breath for idarucizumab, the antidote for dabigatran, to be approved by the FDA. We heard whispers that it was coming for a number of years, even during those rough first few relatively recent years following the approval and widespread use of dabigatran, during which time patients presented to emergency departments across the globe with life-threatening bleeding secondary to dabigatran. Craig and I discussed it in our podcast episode on pipeline reversal [...]